THE HISTORY
OF NEXALIN TECHNOLOGY
2003
Nexalin Gen-1
Clears FDA for the treatment of Anxiety, Depression and Insomnia. Nexalin is presently analyzing prior FDA applications to determine new regulatory strategies for the treatment of Insomnia.
2020 Q1
Nexalin Gen-1
Nexalin begins analyzing 510K application process for Anxiety and Insomnia (postpones Depression PMA)
2020 Q4
China A,D
Nexalin develops and begins research on the China A,D (Alzheimer's and Dementia)
2021 Q2
Nexalin Gen-2
Nexalin develops the Nexalin Gen-2 medical device and begins research with new advanced waveform
2021 Q2
China A,D,I
Nexalin approved by China NMPA for treatment of Depression and Insomnia
2022 Q3
Patient Headset
Nexalin’s Gen-3 technology will be imbedded into a new patient headset medical device. Image is a prototype image.